Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Results View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹868.00

prior close

₹879.55

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.4%+2.4% vs market

Pharmaceuticals peers, median of 147sector+0.5%+2.3% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Smallcap 250 and 2.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.6

10m

+1.8

15m

+0.6

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8+0.4+2.4+0.5+2.3

Next day

+1.7+0.8+1.0-0.2+1.9

+1.2+1.5-0.3-0.3+1.5

-0.7+1.6-2.3-0.4-0.3

-0.8+2.1-2.9-0.1-0.7

-0.6+2.8-3.4-0.1-0.6

-0.5+4.8-5.3+0.5-1.0

15d

+0.7+0.6+0.1-3.0+3.8

+7.0+6.5+0.5-0.2+7.2

+10.6+3.7+6.9+1.2+9.4

-0.6-1.2+0.6-4.2+3.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natco Pharma Limited has filed its financial results for the period ending March 31, 2025, with the stock exchange. This typically covers Q4 FY25 and full-year FY25 performance. The filing marks the company's compliance with quarterly/annual disclosure requirements under listing norms. Specific revenue, profit, and margin figures are not included in the headline and would be available in the detailed results document.

Likely market impact

The filing itself is a routine regulatory submission and does not move the stock. Investors should review the detailed results for revenue growth, profit trends, and margin performance to gauge the company's actual financial health.